A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

NCT ID: NCT01530542

Last Updated: 2012-02-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 5-dosing period study to characterize the pharmacokinetics (process by which oxycodone is absorbed, distributed, metabolized, and eliminated by the body) and the effects of food on the pharmacokinetics of oxycodone. The study will take place over approximately two and a half months and will consist of three phases: a screening visit to determine eligibility for the study, a 5-dosing period treatment phase, and an end-of-study visit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia Acute Pain Chronic Pain Narcotic Abuse Opioid-related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

Group Type EXPERIMENTAL

oxycodone hydrochloride

Intervention Type DRUG

oxycodone hydrochloride 5 mg tablet under fasted conditions

Treatment B

Group Type EXPERIMENTAL

oxycodone hydrochloride

Intervention Type DRUG

2 x oxycodone hydrochloride 5 mg tablets under fasted conditions

Treatment C

Group Type EXPERIMENTAL

oxycodone hydrochloride

Intervention Type DRUG

2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions

Treatment D

Group Type EXPERIMENTAL

oxycodone hydrochloride

Intervention Type DRUG

2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions

Treatment E

Group Type EXPERIMENTAL

marketed oxycodone hydrochloride

Intervention Type DRUG

1 x oxycodone hydrochloride 15 mg tablet under fed conditions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oxycodone hydrochloride

oxycodone hydrochloride 5 mg tablet under fasted conditions

Intervention Type DRUG

oxycodone hydrochloride

2 x oxycodone hydrochloride 5 mg tablets under fasted conditions

Intervention Type DRUG

oxycodone hydrochloride

2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions

Intervention Type DRUG

oxycodone hydrochloride

2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions

Intervention Type DRUG

marketed oxycodone hydrochloride

1 x oxycodone hydrochloride 15 mg tablet under fed conditions

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female subjects between 18 and 55 years of age (inclusive)

Exclusion Criteria

* Evidence or history of clinically significant disease;
* History of obstructive sleep apnea;
* Positive urine drug test.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, Rolleri R. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Clin Ther. 2012 Jul;34(7):1601-12. doi: 10.1016/j.clinthera.2012.05.009. Epub 2012 Jun 19.

Reference Type DERIVED
PMID: 22717418 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B4501006

Identifier Type: -

Identifier Source: secondary_id

K234-10-1001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Abuse Potential Study of PF-00345439
NCT01986283 COMPLETED PHASE1
Targin for Non-cancer Pain
NCT01918098 COMPLETED PHASE3